Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07238556 · ClinicalTrials.gov registry record · NA
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
A NA study of Obesity and Hypertension, sponsored by University of Connecticut.
- Recruiting
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 3
- Study locations
NCT07238556: Recruiting NA study of Obesity and Hypertension, sponsored by University of Connecticut.
NCT07238556 is a NA study of Obesity and Hypertension that is actively recruiting participants, run by University of Connecticut. The registered enrollment target is 72 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07238556, a NA study of Obesity and Hypertension, is actively recruiting participants, sponsored by University of Connecticut.
- RECRUITING
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Primary Outcome
The mHealth Application Usability Questionnaire is validated to measure the usability of mobile health apps for healthcare providers and/or patients through 21 items spilt into three subscales; Ease of Use and Satisfaction, System Information Arrangement, and Usefulness. The rating of each item is scaled from 1 to 7, and responses are averaged to provide a single score. Physicians will rate both P3-EX and American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS), and patients
Conditions Studied
Interventions
- BEHAVIORAL Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants
- BEHAVIORAL Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants
Study Locations (3)
Connecticut
- UConn Health - Farmington
- Hartford HealthCare - Hartford
- University of Connecticut - Storrs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What NCT07238556 shows while recruiting
NCT07238556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants is the first listed.
NCT07238556 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07238556 about?
NCT07238556 is a clinical study titled "A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors". The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with car...
What is the current status of trial NCT07238556?
This trial is currently recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2026-01-01. Estimated completion is 2026-05-31.
What conditions does trial NCT07238556 study?
This clinical trial studies the following conditions: Obesity, Hypertension, Diabetes Mellitus, Cardiovascular Disease, Dyslipidemia.
What interventions are being tested in trial NCT07238556?
The interventions under investigation include: Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants (BEHAVIORAL), Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants (BEHAVIORAL).
Who is sponsoring clinical trial NCT07238556?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07238556 being conducted?
This trial has 3 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07238556's enrollment target sits among peer trials
72 583rd of 1053 higher than 462 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
SMARTer Weight Loss Management
RECRUITING · NA
-
HealthyTogether: RCT of a Dyadic Weight Management Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI